Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPVG.L Regulatory News (PVG)

  • There is currently no data for PVG

EPT Disclosure

15 Mar 2010 11:30

RNS Number : 5775I
Piper Jaffray Ltd
15 March 2010
 

DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS

WITHOUT RECOGNISED INTERMEDIARY STATUS, OR WITH RI STATUS

BUT NOT DEALING IN A CLIENT-SERVING CAPACITY

(Rule 38.5(b) of the Takeover Code)

 

 

1. KEY INFORMATION

 

Name of exempt principal trader

Piper Jaffray Ltd.

Company dealt in

Ark Therapeutics Group PLC 

Class of relevant security to which the dealings being disclosed relate (Note 1)

Ord 1p

Date of dealing

12 March 2010

 

 

2. INTERESTS, SHORT POSITIONS AND RIGHTS TO SUBSCRIBE

 

(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 2)

 

 

 

Long

Short

 

 

Number (%)

Number (%)

(1) Relevant securities

 

122,407 0.06%

(2) Derivatives (other than options)

 

(3) Options and agreements to purchase/sell

 

Total

 

122,407 0.06%

 

(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 2)

 

Class of relevant security:

 

Long

Short

 

 

Number (%)

Number (%)

(1) Relevant securities

 

(2) Derivatives (other than options)

 

(3) Options and agreements to purchase/sell

 

Total

 

 

(c) Rights to subscribe (Note 2)

 

Class of relevant security:

 

Details

 

 

3. DEALINGS (Note 3)

 

(a) Purchases and sales

 

Purchase/sale

 

Number of securities

Price per unit (Note 4)

Buy

78,000

11.50p

 

 

(b) Derivatives transactions (other than options)

 

Product name,

e.g. CFD

Long/short (Note 5)

Number of securities (Note 6)

Price per unit (Note 4)

 

 

 

 

 

(c) Options transactions in respect of existing securities

(i) Writing, selling, purchasing or varying

 

Product name,

e.g. call option

 

Writing, selling, purchasing, varying etc.

Number of securities to which the option relates (Note 6)

Exercise

price

Type, e.g. American, European etc.

Expiry

date

Option money

paid/received per unit (Note 4)

 

 

(ii) Exercising

 

Product name, e.g. call option

Number of securities

Exercise price per unit (Note 4)

 

 

 

 

(d) Other dealings (including new securities) (Note 3)

 

Nature of transaction (Note 7)

 

Details

Price per unit (if applicable) (Note 4)

 

 

 

 

4. OTHER INFORMATION

 

Agreements, arrangements or understandings relating to options or derivatives

 

 

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

 

 

 

 

 

Is a Supplemental Form 38.5(b) attached? (Note 8) NO

 

 

Date of disclosure

15 March 2010

Contact name

Norman Gould

Telephone number

020 3142 8780

Name of offeree/offeror with which connected

Ark Therapeutics Group PLC 

Nature of connection (Note 9)

Adviser and broker

 

 

Notes

 

The Notes on Form 38.5(b) can be viewed on the Takeover Panel's website at www.thetakeoverpanel.org.uk

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
EMMUVUARRWAOAAR
Date   Source Headline
14th Apr 20102:09 pmRNSRule 8.3- Ark Therapeutics Group PLC
14th Apr 201011:41 amRNSEPT Disclosure-Amendment
13th Apr 201012:08 pmBUSRule 8.3 - Ark Therapeutics Group plc
13th Apr 201011:34 amRNSEPT Disclosure
13th Apr 201011:31 amRNSRule 8.3- ARK THERAPEUTICS
13th Apr 201011:29 amRNSEPT Disclosure
12th Apr 201011:22 amRNSEPT Disclosure
12th Apr 201010:19 amRNSEPT Disclosure
12th Apr 20107:00 amRNSResearch Update
9th Apr 201011:35 amRNSEPT Disclosure
9th Apr 201011:33 amRNSEPT Disclosure- Amendment
9th Apr 20109:28 amRNSEPT Disclosure
8th Apr 20102:43 pmRNSEPT Disclosure-Amendment
8th Apr 201012:27 pmRNSEPT Disclosure
8th Apr 201010:43 amRNSRule 8.3- ARK THERAPEUTICS
8th Apr 20108:33 amRNSEPT Disclosure
7th Apr 20104:08 pmRNSAnnual Information Update
7th Apr 201010:59 amRNSRule 8.3- ARK THERAPEUTICS
1st Apr 201011:03 amRNSArk Therapeutics Group plc
1st Apr 201011:00 amRNSEPT Disclosure
1st Apr 201010:37 amRNSEPT Disclosure
31st Mar 20103:42 pmRNSTotal Voting Rights
31st Mar 20102:00 pmBUSRule 8.3 - ARK THERAPEUTICS GROUP PLC
31st Mar 201010:37 amRNSEPT Disclosure
30th Mar 201012:48 pmRNSEPT Disclosure
30th Mar 201012:42 pmBUSRule 8.3 - Ark Therapeutics Group plc
25th Mar 201012:08 pmBUSRule 8.3 - Ark Therapeutics Group plc
25th Mar 201010:53 amRNSEPT Disclosure
24th Mar 201011:52 amRNSEPT Disclosure
24th Mar 201011:15 amRNSEPT Disclosure
24th Mar 201010:25 amBUSRule 8.3 - Ark Therapeutics Group plc
22nd Mar 20101:48 pmRNSRule 8.3- ARK THERAPEUTICS GROUP PLC
22nd Mar 20101:42 pmRNSRule 8.3- ARK THERAPEUTICS GROUP PLC
22nd Mar 20101:24 pmBUSRule 8.3 - ARK THERAPEUTICS GROUP PLC
22nd Mar 201011:45 amRNSEPT Disclosure
22nd Mar 201010:18 amRNSEPT Disclosure
19th Mar 20104:58 pmRNSRule 8.3- (Ark Therapeutics Group Plc)
19th Mar 20102:56 pmRNSRule 8.3- Ark Therapeutics Group plc
19th Mar 20101:30 pmBUSRule 8.3 - Ark Therapeutics Group plc
19th Mar 201011:45 amRNSEPT Disclosure
19th Mar 201010:30 amRNSEPT Disclosure
18th Mar 201012:14 pmRNSEPT Disclosure
17th Mar 201010:38 amRNSEPT Disclosure
16th Mar 20103:55 pmRNSHolding(s) in Company
16th Mar 201011:12 amRNSEPT Disclosure
15th Mar 201011:30 amRNSEPT Disclosure
15th Mar 201010:34 amRNSEPT Disclosure
11th Mar 201011:49 amRNSEPT Disclosure
10th Mar 20104:40 pmRNSSecond Price Monitoring Extn
10th Mar 20104:35 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.